Recent performance context for LivaNova (LIVN)

LivaNova (LIVN) has drawn attention after a period of solid share price performance, with the stock up around 4% over the past month and about 21% over the past 3 months.

At a share price of about $74.80, LivaNova’s recent 1-day share price return of 3.37% and 90-day share price return of 20.78%, alongside a 1-year total shareholder return of 61.56%, point to building momentum rather than a short-lived bounce.

If you are thinking about where else strong momentum could emerge in healthcare, it may be worth scanning for other opportunities across 39 healthcare AI stocks

With LivaNova trading around $74.80 and sitting at a discount to some intrinsic value estimates and analyst targets, the question is whether there is still undervalued potential or the market is already pricing in future growth.

Most Popular Narrative: 6.7% Undervalued

The most followed valuation narrative puts LivaNova’s fair value at about $80.18, a touch above the recent $74.80 close, which frames the current debate around upside.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Want to see what sits behind that confidence in higher margins and premium therapies? The narrative leans on compound revenue growth, rising profitability and a richer earnings multiple to justify its fair value.

Result: Fair Value of $80.18 (UNDERVALUED)

However, this depends on LivaNova avoiding pressure from tighter reimbursement and cost controls, as well as newer therapies gaining traction without regulatory or safety setbacks.

Next Steps

Comfortable with the upbeat tone so far, but want to stress test it yourself before the market moves on? Take a moment to review the 3 key rewards

Looking for more investment ideas?

If LivaNova is on your radar, do not stop there. A wider watchlist built from high quality filters can reveal opportunities you might otherwise miss.

• Spot potential bargains early and let the data guide you toward quality with the 47 high quality undervalued stocks.
• Prioritize resilience by scanning companies with robust finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Uncover lesser known opportunities that meet strict fundamentals by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.